Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 10« First...678910

Shire Kills Baxalta’s Hemophilia B Program; Clears Path for BioMarin, Spark Therapeutics and uniQure

When companies merge, there is almost always fallout – sometimes it’s jobs and sometimes it’s programs. When Shire acquired Bannockburn, Ill.-based Baxalta earlier in 2016, a certain number of job cuts were expected, and on May 1, Baxalta laid off 239 people. Then during the company’s second-quarter 2016 finances conference call, Shire indicated it was killing what had seemed to be a very promising hemophilia B program, BAX 335.

Read More »

Pfizer Boss Won’t Commit to a Company Split, But Decision Might Depend on Whether Clinton or Trump Wins the U.S. Presidential Election

Even before the Pfizer-Allergan merger was announced and then fell apart, Pfizer was discussing the possibility of splitting the company into two. The idea was that the company would break into one that focused on newer, faster-growing products, and another that focused on mature, branded drugs that often had expired patents. But at the company’s second-quarter 2016 earnings conference call, Pfizer chief executive Ian Read indicated that may no longer be on the table.

Read More »

India’s Aurobindo Pharma Breaks Ground on U.S. HQ, Will Create Up to 400 Jobs

Aurobindo USA, a subsidiary of India-based Aurobindo Pharma, has broken ground on its planned 575,000 square-foot manufacturing and distribution facility – a site expected to bring up to 400 new jobs.

Read More »

U.S. officials provide stopgap Zika funds, Congress urged to act

Federal health officials, scrambling to fund efforts to combat the spread of the Zika virus in the United States, said they have provided more stopgap money to various locales while calls grew for Congress to cut short its recess and act.

Read More »

Pfizer in settlement of Celebrex, Bextra litigation

Pfizer reached a $486 million settlement of litigation accusing it of causing big losses for shareholders by concealing safety risks associated with the pain relievers.

Read More »

Few seniors seeking health advice from Dr. Google

Even though most seniors have cell phones and computers, they still do not go online to find answers to medical questions, contact doctors or fill prescriptions, a U.S. study suggests.

Read More »

Pfizer beats estimates; branded drugs disappoint

Pfizer Inc. reported better-than-expected second-quarter 2016 results, but revenue from its branded patent-protected medicines brought disappointment.

Read More »

China’s ‘mosquito factory’ aims to wipe out Zika, other diseases

Every week, scientists in southern China release 3 million bacteria-infected mosquitoes on a 3 km (two-mile) long island in a bid to wipe out diseases such as dengue, yellow fever and Zika.

Read More »

UK court says state health system can fund preventative HIV drug

A high court judge ruled that an HIV pill to prevent infection can be funded by the state health service in England, in a victory for AIDS campaigners who have been calling for its widespread use.

Read More »

Amgen Forges Pre-clinical R&D Pact With Advaxis

Amgen Inc. struck a research and development deal for the development of Advaxis Inc.’s pre-clinical immunotherapy treatment, ADXS-NEO.

Read More »

Struggling Telesta Cuts Another 30% of Workforce

Telesta Therapeutics will terminate its bladder cancer drug MCNA project, shutter its Montreal-based manufacturing facility and terminate another 30 percent of its workforce.

Read More »

Another Round of Layoffs for Pfizer in New York

As Pfizer winds down its vaccine production at its Pearl River site, Pfizer has plans to lay off an additional 151 employees – completing a process that began in 2010 when the company opted to phase out vaccine production at the site.

Read More »

Virtus Pharmaceuticals Inc. Announces Launch of Prometrium (Progesterone, USP Capsules)

Virtus Pharmaceuticals Inc. – a specialty niche pharmaceutical company and part of the Linden Capital Partners portfolio – announced it launched Prometrium (Progesterone, USP Capsules), the company’s first branded product.

Read More »

Biogen exercises option to develop muscle drug after trial success

Biogen Inc. said it would exercise an option to develop and commercialize an experimental genetic muscle-disorder drug after an interim analysis of late-stage data showed patients experienced statistically significant improvement.

Read More »

Keryx withdraws 2016 forecast on renal drug supply disruption

Keryx Biopharmaceuticals Inc. withdrew its full-year 2016 forecast due to a disruption in production of its only approved drug, Auryxia.

Read More »

Pfizer acquires Bamboo Therapeutics

Pfizer acquired privately held gene therapy developer Bamboo Therapeutics in a deal worth up to $645 million to boost its presence in the treatment of rare diseases.

Read More »

Pharma and tech converge in ‘fantastic voyage’ to fight disease

The line between pharmaceuticals and technology is blurring as companies join forces to tackle chronic diseases using high-tech devices that combine biology, software and hardware.

Read More »

Celgene Accused of ‘Scheme to Gain Billions’

Allegations were made that Celgene donated millions of dollars to charities that help patients afford high-priced cancer drugs as part of a profit-making scheme.

Read More »

GSK and Verily forge bioelectronic medicines firm

GSK and Google parent Alphabet’s life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body.

Read More »

Page 10 of 10« First...678910

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom